Marcus Schindler, Novo Nordisk CSO (Ryan Cross for Endpoints News)

No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

LEX­ING­TON, Mass. — The world’s sec­ond-most valu­able phar­ma com­pa­ny is on the hunt for its next big break­through, and it thinks the se­quel to Ozem­pic or We­govy could be dis­cov­ered in Boston.

On Wednes­day, the Dan­ish di­a­betes and obe­si­ty drug­mak­er No­vo Nordisk un­veiled its new R&D fa­cil­i­ty just out­side the city, pitch­ing it as a US flag­ship to match its head­quar­ters in Den­mark, and an im­por­tant step to­wards life af­ter its block­buster GLP-1 drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.